A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.

Cryptosporidium is recognized as one of the main causes of childhood diarrhea worldwide. However, the current treatment for cryptosporidiosis is suboptimal. Calcium flux is essential for entry in apicomplexan parasites. Calcium-dependent protein kinases (CDPKs) are distinct from protein kinases of mammals, and the CDPK1 of the apicomplexan Cryptosporidium lack side chains that typically block a hydrophobic pocket in protein kinases. We exploited this to develop bumped kinase inhibitors (BKIs) that selectively target CDPK1. We have shown that several BKIs of Cryptosporidium CDPK1 potently reduce enzymatic activity and decrease parasite numbers when tested in vitro. In the present work, we studied the anticryptosporidial activity of BKI-1517, a novel BKI. The half maximal effective concentration for Cryptosporidium parvum in HCT-8 cells was determined to be approximately 50 nM. Silencing experiments of CDPK1 suggest that BKI-1517 acts on CDPK1 as its primary target. In a mouse model of chronic infection, 5 of 6 SCID/beige mice (83.3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517. No side effects were observed. These data support advancing BKI-1517 as a lead compound for drug development for cryptosporidiosis.

[1]  Nicolas Perry,et al.  Preassembled Single-Stranded RNA-Argonaute Complexes: A Novel Method to Silence Genes in Cryptosporidium. , 2015, The Journal of infectious diseases.

[2]  K. Shokat,et al.  Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture , 2015, Antimicrobial Agents and Chemotherapy.

[3]  A. White,et al.  Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward , 2015, Current Tropical Medicine Reports.

[4]  E. Merritt,et al.  The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites , 2014, Parasitology.

[5]  Dustin J Maly,et al.  Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold. , 2014, ACS medicinal chemistry letters.

[6]  Dustin J Maly,et al.  A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. , 2013, The Journal of infectious diseases.

[7]  Inacio Mandomando,et al.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.

[8]  Sean R. Moore,et al.  The impoverished gut—a triple burden of diarrhoea, stunting and chronic disease , 2013, Nature Reviews Gastroenterology &Hepatology.

[9]  Karen L. Kotloff,et al.  Burden of disease from cryptosporidiosis , 2012, Current opinion in infectious diseases.

[10]  Steven M. Johnson,et al.  Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. , 2012, Bioorganic & medicinal chemistry letters.

[11]  F. Rossi,et al.  The potent antiplasmodial calmodulin-antagonist trifluoperazine inhibits plasmodium falciparum calcium-dependent protein kinase 4. , 2011, Protein and peptide letters.

[12]  Dustin J Maly,et al.  Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii , 2010 .

[13]  Dustin J Maly,et al.  Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors , 2010, Nature Structural &Molecular Biology.

[14]  R. Haque,et al.  Attribution of malnutrition to cause-specific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. , 2009, The American journal of tropical medicine and hygiene.

[15]  J. Rossignol,et al.  Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. , 2001, The Journal of infectious diseases.

[16]  D. Zygmunt.  Cryptosporidium Species , 1989, Infection Control & Hospital Epidemiology.

[17]  Dustin J Maly,et al.  Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. , 2010, ACS medicinal chemistry letters.

[18]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .